Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00491322 · ClinicalTrials.gov registry record · NA
Vitamin D Deficiency, Insulin Resistance and FGF-23
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
NCT00491322: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00491322 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 92 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00491322, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this project is to determine if treating vitamin D deficiency decreases insulin resistance and improves insulin secretion in healthy volunteers. Additionally, this project will investigate if treating vitamin D deficiency affects a new phosphate-regulating hormone called FGF-23.
Primary Outcome
Fibroblast growth factor 23 (FGF23) is a phosphate and vitamin D regulating hormone.
Interventions
- DIETARY_SUPPLEMENT Ergocalciferol
- DIETARY_SUPPLEMENT Ergocalciferol placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-02 |
| Phase | NA |
What the finished NCT00491322 record still lists
NCT00491322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Ergocalciferol is the first listed.
NCT00491322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00491322 about?
NCT00491322 is a clinical study titled "Vitamin D Deficiency, Insulin Resistance and FGF-23". The purpose of this project is to determine if treating vitamin D deficiency decreases insulin resistance and improves insulin secretion in healthy volunteers. Additionally, this project will investigate if treating vitamin D deficiency affects a new phosphate-regulating hormone called FGF-23.
What is the current status of trial NCT00491322?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2006-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00491322?
The interventions under investigation include: Ergocalciferol (DIETARY_SUPPLEMENT), Ergocalciferol placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00491322?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00491322's enrollment target sits among peer trials
92 937th of 2000 higher than 1,062 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia